

REMARKS

In reply to the Restriction Requirement that was mailed in connection with the above-captioned patent application on March 22, 2006, Applicants elect the claims of Group I, drawn to methods for preventing and/or treating an amyloid-related disease in a subject, comprising administering an antigenic peptide, and the species of SEQ ID NO: 13, with traverse.

Applicants respectfully submit that all of the present claims should be considered to fall within a single group for the purposes of Restriction analysis, as new claims 46-61 specify methods of use of a particular vaccine, and new claims 62-72 specify that particular vaccine itself. Thus, the inventions of these claims are related products and processes, wherein the vaccines are used in the vaccination methods, and the vaccination methods employ the vaccines. In view of the relationship between the claimed methods and vaccines, Applicants submit that the claims of Groups I and II should be examined together.

With respect to the species election, Applicants submit that the dependent claims specifying additional sequences (i.e., SEQ ID NOs: 3, 4, 7, 10, 15, 18, 21, 23, 25, 26, 27, 50, 53, 56, 59, and 62, which are specified in claims 47-50 and 63-66) should be examined in addition to SEQ ID NO: 13, as each of these sequences encompasses SEQ ID NO: 13.

Applicants submit that the present amendment does not add new matter. Referring to the published application, we point to the following support for the above-noted amendments.

- Support for the term: “a vaccine for generating anti-amyloidogenic antibodies” in independent claims 46, 61, and 62 can be found in Paragraph 63 (last sentence).
- Claims 47-50 and 63-66 are supported by Paragraphs 89 to 154;
- Claims 51 and 67 are supported by Paragraphs 73 to 82;

- Claims 52, 53, 68, and 69 are supported by the references to “protein conjugates” in Paragraphs 21 and 47; the references to carriers at Paragraphs 67 to 70; the description of Fig. 7 at Paragraph 54; Example I (Paragraphs 161 to 165); and Figure 7;
- Claims 54, 55, 70, and 71 are supported by Paragraph 69;
- Claims 56 and 57 are supported by the application as a whole and in particular by Paragraphs 46 and 63-66; Examples I to III (Paragraphs 161 to 172), and associated Figures 2 to 7;
- Claims 58 to 60 are supported, for example, in Paragraphs 58 and 72;
- Claims 61 and 62 are supported in the application as a whole and, in particular, by Paragraphs 47 and 62; and
- Claim 72 is supported, for example, by Paragraph 72.

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 20, 2006

Susan M. Michaud
 Susan M. Michaud, Ph.D.
 Reg. No. 42,885

Clark & Elbing LLP
 101 Federal Street
 Boston, MA 02110
 Telephone: 617-428-0200
 Facsimile: 617-428-7045